Meningitis Research Foundation Ireland said on Wednesday that the National Immunisation Advisory Committee will make a meningococcal disease group B vaccine a priority after it was recommended for use in the U.K.
The Bexsero vaccine was recommended by the Joint Committee on Vaccination and Immunisation for use with infants. The recommended application involved administering doses to infants 2, 4, and 12 months of age.
NIAC said it discussed using the vaccine at its March 24 meeting and said it is looking for more information before presenting a recommendation.
"MenB kills and disables more children in Ireland than any other infectious disease," Meningitis Research Foundation Manager Diane McConnell said. "That's why this charity and our supporters have campaigned so hard for this vaccine. We applaud the decision taken by the JCVI, which means children in Northern Ireland will be protected from this deadly disease, and are hopeful that NIAC will also recognize the importance of this vaccine and introduce it here too."
Bexsero is produced by Novartis Vaccines and was licensed by the European Union in January 2013.
The Meningitis Research Foundation is a nonprofit focused on eliminating meningitis and septicemia. The foundation works to raise funding for education and awareness campaigns, works with health professionals to develop and publish guidelines for treatment and works as a support network for those already infected.